http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102042456-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06 |
| filingDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102042456-B1 |
| titleOfInvention | Preparation for percutaneous absorption |
| abstract | The present invention relates to a transdermal absorption preparation containing polmacoxib, while maintaining the properties such as medicament and effective amount of polmacoxib, while minimizing the effects from exogenous and endogenous factors and maintaining a stable blood concentration for a certain time It relates to a formulation that can be made. In addition, side effects of the organs due to administration of the agent can be minimized and the frequency of administration can be reduced, thereby increasing compliance with the patient. |
| priorityDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.